Skip to NavigationSkip to content

Business Services

Living with acute myeloid leukaemia

Published on 23/09/19 at 11:48am

Steve Rothberg was blindsided by an AML diagnosis that progressed rapidly with little warning. Ten years later, he discusses his outlook and strategies during the intensive treatment, and how a coincidental GP visit and a stem cell transplant changed the course of what might have been.

What originally alerted you to the fact that something was off with your physical health?

Poor diabetes control costing NHS £3bn in avoidable treatment

3 pound coins

Findings being presented at this year’s European Association for the Study of Diabetes have shown that the NHS is losing £3 billion every year in potentially avoidable hospital diabetes treatment in England.

The study revealed that on average people with type 1 diabetes require six times more hospital treatment (£3,035 per person per year) than those without the condition (£510). Individuals with type 2 diabetes also required twice as much care, after adjusting for their older age with a figure that stood at £1,291 per annum.

UKRI Chief Executive Sir Mark Walport to step down in 2020

Published on: 17/09/19

Sir Mark Walport, Chief Executive of UK Research and Innovation (UKRI), the national funding agency responsible for science and research investment in the UK, has announced he is to retire for the role next year.

The decision to leave the organisation in 2020 will mark the end of a three-year tenure at its helm, beginning in 2017 when Walport was appointed to “create a single, ambitious organisation and provide the UK with a world class funding system to keep it at the forefront of global research and innovation”.

Jerome Carle steps down as Julphar Chief Executive

Published on: 16/09/19

Chief Executive of Gulf Pharmaceutical Industries, Jerome Carle, is stepping down from his post at the United Arab Emirates drug manufacturer facing mounting pressure.

Julphar, one of the biggest generic drugs manufacturers in the Middle East and North Africa said Jerome Carle has “tendered his resignation” and the board has accepted it. His last working day will be December 8th.

Breaking through limits in lung cancer: Introducing The Lung Ambition Alliance

Published on 16/09/19 at 11:40am

Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, at AstraZeneca, discusses his company’s role in the Lung Ambition Alliance and its strategy for supercharging outcomes for lung cancer patients.

Among men, lung cancer is the leading cause of cancer‐related deaths in 87 countries, and among women in 26 countries. All told, lung cancer is responsible for nearly one in five cancer deaths worldwide. And in many countries, including the US and UK, lung cancer is the number one cancer killer.

Top Ten most popular articles on Pharmafile.com this week

It’s Friday again and time for another rundown of the top most popular articles on Pharmafile.com this week. This past week saw Novo Nordisk launch a huge price cut for its insulin drug Novolog as well as good and bad news for Bristol Myers Squibb’s Opdivo.

10. Vertex cystic fibrosis drugs become available in Scotland after NHS rejection

UKRI Chief Executive Sir Mark Walport to step down in 2020

Sir Mark Walport, Chief Executive of UK Research and Innovation (UKRI), the national funding agency responsible for science and research investment in the UK, has announced he is to retire for the role next year.

The decision to leave the organisation in 2020 will mark the end of a three-year tenure at its helm, beginning in 2017 when Walport was appointed to “create a single, ambitious organisation and provide the UK with a world class funding system to keep it at the forefront of global research and innovation”.

Read the September edition of Pharmafocus online now!

The latest monthly edition of Pharmafocus, the September issue, is available to read for free online now!

With a new Prime Minister, a renewed drive to vacate the European Union by the fixed date of 31 October by any means necessary, but a distinct lack of any tangible negotiation strategy – or indeed, any evidence of negotiations at all – the UK looks to be hurtling towards a no-deal Brexit.

Former Ergomed CEO appointed as Midatech’s Chief Financial Officer

Published on: 11/09/19

Immunotherapy-focused pharmaceutical company Midatech Pharma has appointed Stephen Stamp as Chief Financial Officer (CFO) with immediate effect.

He will be replacing Nick Robbins-Cherry, who has stepped down after five years since joining in 2014. Robbins will nevertheless remain at Midatech until October to facilitate Stamp’s handover in an orderly fashion.

Stamp has most recently served as CEO of pharmaceutical firm Ergomed for two years, stepping down in January citing health reasons. Prior to this he was CFO at Ergomed for a year beginning in 2016.

Tony Coles appointed to Pfizer Spinout Cerevel as CEO

Published on: 10/09/19

Cerevel Therapeutics, a pharmaceutical company dedicated to treating neurological diseases, has appointed renowned biotechnology leader Tony Coles as Chief Executive Officer (CEO).

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches